Browse news, stories, events, and press items with a focus on fine chemical supply, quality systems, sustainability reporting, and regulatory documentation.
A quality manager's perspective on why surface-level specification compliance can hide deeper issues in pharma manufacturing, and how a structured approach to verification prevents costly rework.
Read moreA procurement manager explains why total cost of ownership (TCO) is the only metric that matters when choosing a CDMO like Lonza, based on 6 years of tracking vendor spend.
Read moreA procurement manager shares his experience of switching to Lonza for lab chemicals and APIs, reducing total cost of ownership while ensuring GMP compliance and reliable SDS documentation.
Read moreAn industry insider argues that the ability to handle true rush orders is a fundamental test of a CDMO's operational maturity, using real-world examples from pharmaceutical and biotech manufacturing.
Read moreA no-fluff perspective on when to turn to Lonza for pharma APIs, specialty chemicals, and when you'd be wasting your time — based on real rush-order experience.
Read moreA hands-on guide from someone who learned the hard way: when you need fill-finish for commercial pharma operations, speed isn't a luxury — it's a lifeline. Three scenarios, one decision tree, and the mistakes that taught me the real cost of 'cheap and fast'.
Read moreAn emergency specialist breaks down how to navigate Lonza’s vast website, what their brand really signals to pharma buyers, and why pharma-grade DMSO matters for surfactant-related research.
Read moreA supply manager's no-fluff comparison of Lonza vs. small CDMOs and generic suppliers, drawing on 13 years of costly mistakes to help you decide when the premium is worth it and when it's not.
Read moreA procurement manager shares why the cheapest supplier for cell culture media and chemicals often costs more in the long run, using Lonza's PBS formulation as a case study in total cost of ownership.
Read moreAn honest look at why focusing solely on price can cost your organization more in the long run, based on real-world procurement experience in the pharmaceutical and biotech supply chain.
Read more